These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16680756)

  • 1. Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis.
    Ozdemir E; Koc Y; Kansu E
    Am J Hematol; 2006 Jun; 81(6):474. PubMed ID: 16680756
    [No Abstract]   [Full Text] [Related]  

  • 2. Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML.
    Lazarevic V; Golovleva I; Nygren I; Wahlin A
    Am J Hematol; 2006 Jun; 81(6):470-1. PubMed ID: 16680752
    [No Abstract]   [Full Text] [Related]  

  • 3. [Molecular relapse of chronic myeloid leukemia after discontinuation of imatinib mesylate for maintaining complete molecular response for more than 2 years].
    Kiguchi T; Tauchi T; Ohyashiki K
    Rinsho Ketsueki; 2009 Jan; 50(1):52-4. PubMed ID: 19225231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease.
    Franceschino A; Tornaghi L; Piazza R; Pogliani E; Gambacorti Passerini C
    Haematologica; 2006 Jun; 91(6 Suppl):ECR14. PubMed ID: 16785120
    [No Abstract]   [Full Text] [Related]  

  • 5. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature.
    Guastafierro S; Falcone U; Celentano M; Coppola M; Ferrara MG; Sica A
    Leuk Res; 2009 Aug; 33(8):1079-81. PubMed ID: 19167064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate as a cause of acute liver failure.
    Cross TJ; Bagot C; Portmann B; Wendon J; Gillett D
    Am J Hematol; 2006 Mar; 81(3):189-92. PubMed ID: 16493605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission.
    Carella AM; Lerma E
    Ann Hematol; 2007 Oct; 86(10):749-52. PubMed ID: 17576558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up.
    Breccia M; Stagno F; Vigneri P; Latagliata R; Cannella L; Del Fabro V; Di Raimondo F; Alimena G
    Am J Hematol; 2010 May; 85(5):375-7. PubMed ID: 20306543
    [No Abstract]   [Full Text] [Related]  

  • 9. What is the dose of STI-571 needed to induce a molecular remission in chronic myeloid leukemia?
    Ruiz-Argüelles GJ
    Haematologica; 2002 Mar; 87(3):ELT15. PubMed ID: 11869961
    [No Abstract]   [Full Text] [Related]  

  • 10. Strategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia.
    Singh T; Casson C
    Am J Ther; 2007; 14(5):484-7. PubMed ID: 17890939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib.
    Woo SM; Huh CH; Park KC; Youn SW
    J Dermatol; 2007 Oct; 34(10):724-6. PubMed ID: 17908148
    [No Abstract]   [Full Text] [Related]  

  • 12. Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia.
    Oztas P; Erbasi S; Lenk N; Polat M; Han O; Artuz F; Alli N
    Acta Derm Venereol; 2006; 86(2):174-5. PubMed ID: 16648930
    [No Abstract]   [Full Text] [Related]  

  • 13. Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia: before or after imatinib?
    Tefferi A
    Cancer; 2011 Jan; 117(2):234-7. PubMed ID: 21210471
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia.
    Miyachi K; Ihara A; Hankins RW; Murai R; Maehiro S; Miyashita H
    Clin Rheumatol; 2003 Oct; 22(4-5):329-32. PubMed ID: 14576993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia.
    Mahon FX; Molimard M
    Leuk Res; 2009 Aug; 33(8):1147-8; author reply 1149-50. PubMed ID: 19395027
    [No Abstract]   [Full Text] [Related]  

  • 16. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
    François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
    Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
    Qin YZ; Jiang B; Jiang Q; Zhang Y; Jiang H; Li JL; Zhu HH; Li LD; Liu YR; Chen SS; Huang XJ
    Acta Haematol; 2008; 120(3):146-9. PubMed ID: 19039205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Imatinib mesylate plus G-CSF therapy for chronic myelogenous leukemia in the blastic crisis].
    Morita R; Hashino S; Sogabe S; Dazai M; Onozawa M; Izumiyama K; Kondo T; Ota S; Kobayashi S; Imamura M; Asaka M
    Rinsho Ketsueki; 2004 Oct; 45(10):1105-10. PubMed ID: 15553045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intestinal bleeding during the treatment of chronic myeloid leukemia with imatinib mesylate].
    Yokote T; Akioka T; Nakayama S; Oka S; Hara S; Yamano T; Tsuji M; Hanafusa T
    Rinsho Ketsueki; 2005 Sep; 46(9):1060-4. PubMed ID: 16440765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib.
    Franceschino A; Tornaghi L; Benemacher V; Assouline S; Gambacorti-Passerini C
    Haematologica; 2008 Feb; 93(2):317-8. PubMed ID: 18245661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.